Immunocore (NASDAQ:IMCR – Get Free Report) and Palisade Bio (NASDAQ:PALI – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.
Volatility & Risk
Immunocore has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500. Comparatively, Palisade Bio has a beta of 1.36, suggesting that its share price is 36% more volatile than the S&P 500.
Profitability
This table compares Immunocore and Palisade Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Immunocore | -15.87% | -12.84% | -5.09% |
| Palisade Bio | N/A | -148.51% | -115.16% |
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Immunocore | $296.31 million | 5.50 | -$55.29 million | ($0.95) | -34.27 |
| Palisade Bio | $250,000.00 | 12.92 | -$12.30 million | ($13.98) | -0.17 |
Palisade Bio has lower revenue, but higher earnings than Immunocore. Immunocore is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
84.5% of Immunocore shares are owned by institutional investors. Comparatively, 11.8% of Palisade Bio shares are owned by institutional investors. 9.1% of Immunocore shares are owned by insiders. Comparatively, 3.3% of Palisade Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Analyst Ratings
This is a summary of current ratings and recommmendations for Immunocore and Palisade Bio, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Immunocore | 1 | 3 | 9 | 0 | 2.62 |
| Palisade Bio | 0 | 0 | 1 | 0 | 3.00 |
Immunocore currently has a consensus price target of $69.18, indicating a potential upside of 112.47%. Palisade Bio has a consensus price target of $8.00, indicating a potential upside of 229.22%. Given Palisade Bio’s stronger consensus rating and higher possible upside, analysts plainly believe Palisade Bio is more favorable than Immunocore.
About Immunocore
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company’s product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
About Palisade Bio
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.
Receive News & Ratings for Immunocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunocore and related companies with MarketBeat.com's FREE daily email newsletter.
